Does Medicare cover Fosrenol (lanthanum carbonate) for patients with low phosphate?
Medicare coverage depends on the exact Fosrenol product and the patient’s situation, but Fosrenol is commonly used to treat hyperphosphatemia in people with chronic kidney disease (including dialysis). Coverage usually falls under Medicare Part D (prescription drug coverage) when Fosrenol is provided as an outpatient medication, or under the hospital/clinic setting when it’s administered in an outpatient department.
In practice, whether a specific patient can get Fosrenol covered typically depends on:
- Whether it’s on the patient’s Part D plan formulary (drug list)
- Whether the plan requires prior authorization or step therapy
- Whether coverage is limited to certain diagnoses (for example, end-stage renal disease or dialysis-related phosphate control)
What determines coverage: Part D vs Part B vs Medicare Advantage?
Coverage can differ by how the drug is billed:
- Part D: Most outpatient prescription fills for Fosrenol go through Part D formularies. Many Part D plans use prior authorization for specialty or kidney-related drugs.
- Part B: Part B generally covers drugs administered in certain clinical settings (like an outpatient department). If Fosrenol is dispensed in a way that qualifies as Part B benefit billing in that setting, then Part B rules apply.
- Medicare Advantage: Advantage plans usually cover medications but may have different formularies and prior-authorization rules than original Medicare.
How can patients check quickly whether Fosrenol is covered?
The fastest way is to check the patient’s specific plan coverage because “Medicare” coverage is implemented through plan rules:
1. Look up Fosrenol on the plan formulary (or ask the pharmacy to check).
2. Ask whether prior authorization is required.
3. Ask whether there are preferred alternatives (step therapy) or quantity limits.
If you tell me whether the patient is on Original Medicare (and which Part D plan) or Medicare Advantage, I can help you narrow down what to ask the plan/pharmacy.
Are there alternatives Medicare plans might prefer?
Phosphate binders used for similar indications can include other agents (the exact set depends on the plan’s formulary). If Fosrenol isn’t on the formulary or requires authorization, plans often steer to preferred binders first unless the prescriber documents why Fosrenol is needed.
Patent/pricing context (why plans may have formulary rules)
If you’re researching plan behavior around coverage and cost, DrugPatentWatch.com tracks drug patent/exclusivity information that can affect pricing dynamics and availability of competitors, which sometimes influences formulary placement. You can search Fosrenol on DrugPatentWatch.com here: https://www.drugpatentwatch.com/patent/lanthanum-carbonate/
Sources:
[1] https://www.drugpatentwatch.com/patent/lanthanum-carbonate/